UBS AM’s AMAG Pharmaceuticals AMAG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-18,226
Closed -$171K 2614
2020
Q3
$171K Sell
18,226
-15,482
-46% -$147K ﹤0.01% 2420
2020
Q2
$258K Sell
33,708
-8,517
-20% -$65.2K ﹤0.01% 2329
2020
Q1
$261K Sell
42,225
-921
-2% -$8.11K ﹤0.01% 2195
2019
Q4
$525K Buy
43,146
+2,084
+5% +$22.8K ﹤0.01% 2217
2019
Q3
$474K Buy
41,062
+14,087
+52% +$148K ﹤0.01% 2316
2019
Q2
$269K Buy
26,975
+14,876
+123% +$160K ﹤0.01% 2444
2019
Q1
$156K Hold
12,099
﹤0.01% 2519
2018
Q4
$184K Hold
12,099
﹤0.01% 2411
2018
Q3
$242K Hold
12,099
﹤0.01% 2357
2018
Q2
$236K Hold
12,099
﹤0.01% 2407
2018
Q1
$244K Buy
+12,099
New +$205K ﹤0.01% 2302
2017
Q1
Sell
-8,199
Closed -$285K 2504
2016
Q4
$285K Sell
8,199
-8,457
-51% -$253K ﹤0.01% 1963
2016
Q3
$408K Hold
16,656
﹤0.01% 2098
2016
Q2
$398K Buy
16,656
+3,200
+24% +$73.4K ﹤0.01% 2078
2016
Q1
$315K Sell
13,456
-800
-6% -$19K ﹤0.01% 2188
2015
Q4
$430K Hold
14,256
﹤0.01% 2137
2015
Q3
$566K Buy
14,256
+3,457
+32% +$215K ﹤0.01% 1957
2015
Q2
$746K Buy
10,799
+2,200
+26% +$138K ﹤0.01% 1835
2015
Q1
$470K Buy
8,599
+2,300
+37% +$110K ﹤0.01% 2006
2014
Q4
$268K Hold
6,299
﹤0.01% 2301
2014
Q3
$201K Buy
+6,299
New +$134K ﹤0.01% 2382

UBS AM's AMAG Position: Q4 2020 in Review

UBS AM sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 18,226 shares — an estimated $171K sold.

UBS AM first reported a position in AMAG in Q3 2014 and held it in 21 quarters. The position peaked at $746K in Q2 2015. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.

  • UBS AM reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • UBS AM sold 18,226 AMAG Pharmaceuticals shares in Q4 2020, an estimated $171K.
  • UBS AM first reported a position in AMAG Pharmaceuticals in Q3 2014 and held it in 21 quarters.
  • UBS AM's AMAG Pharmaceuticals position peaked at $746K in Q2 2015.
  • 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.

Based on UBS AM's 13F filing for Q4 2020, filed 17 Feb 2021.